Loading...
•
Sep 30
Boston Scientific Q3 2025 Earnings Report
Boston Scientific reported strong revenue and earnings growth during the third quarter of 2025.
Key Takeaways
Boston Scientific delivered a robust Q3 2025 performance, driven by significant revenue gains and higher net income, particularly in the U.S. and Cardiovascular segments.
Revenue grew to $5.065 billion, up from $4.209 billion a year ago.
GAAP EPS came in at $0.51; adjusted EPS was $0.75.
Net income reached $755 million, up from $469 million in Q3 2024.
Cardiovascular and MedSurg segments posted strong organic growth.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia-Pacific Revenue
CapyFin.comLatin America & Canada Revenue
CapyFin.comEmerging Markets Revenue
CapyFin.com Forward Guidance
Boston Scientific expects continued growth into Q4 and full year 2025, forecasting double-digit sales increases and strong EPS performance.
Positive Outlook
- Q4 2025 organic revenue growth expected between 11% and 13%
- Q4 GAAP EPS guided between $0.48 and $0.52
- Q4 adjusted EPS guided between $0.77 and $0.79
- Full-year 2025 GAAP EPS expected between $1.97 and $2.01
- Full-year adjusted EPS expected between $3.02 and $3.04
Challenges Ahead
- Foreign currency expected to have a ~2% negative impact in Q4
- Guidance reflects reduced ACURATE valve sales after discontinuation
- Organic growth decelerates slightly in Q4 compared to Q3
- No guidance provided for free cash flow or capital expenditures
- Europe (EMEA) posted operational decline of 2% in Q3
Revenue & Expenses
Visualization of income flow from segment revenue to net income